ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cellsRicardo Parrondo, Carlos Perez‐Stable|PeerJ|2013Cited by 56
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Zi Chen et al.|Clinical Cancer Research|2023Cited by 38
Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age ReportingThejus Jayakrishnan, Sikander Ailawadhi, Sonikpreet Aulakh et al.|Cancers|2021Cited by 20
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparitiesSikander Ailawadhi, Asher Chanan‐Khan, Yaw Adu et al.|Blood Cancer Journal|2024Cited by 8
Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and DisparitiesYaw Adu, Sikander Ailawadhi, Saurav Das et al.|Blood|2023Cited by 3